Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Taiwan's TLC Granted Orphan Status in US for Lymphoma Drug

publication date: Oct 20, 2016
TLC, a Taiwan novel drug maker, was granted Orphan Drug designation in the US for TLC178, an oral drug that targets cutaneous T-cell lymphoma. Lymphoma is one of the most common forms of blood cancer, and cutaneous T-cell lymphoma is a common T-cell lymphoma. Two weeks ago, TLC was approved to begin US trials of TLC178. TLC178, a lipid-encapsulated form of vinorelbine, is a targeted form of the chemotherapy that is designed to increase efficacy and lower toxicity. More details....

Stock Symbol: (TT: 4152)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital